On the contrary, studies in mild-moderate asthmatics documented Mepolizumab to be ineffective in improving end-point clinical symptoms (refer to Table 1, [16, 19, 20]), therefore raising concern over the efficacy of IL-5 as a therapeutic intervention in asthma. The gene discussed is IL5; the disease is asthma.